Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 209-214, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Genser, N.
Right arrow Articles by Mair, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Genser, N.
Right arrow Articles by Mair, J.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1998;44:209-214.)
© 1998 American Association for Clinical Chemistry, Inc.

Enzymes and Protein Markers

Rebound increase of plasminogen activator inhibitor type 1 after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used

Norbert Genser1, Peter Lechleitner1, Josef Maier1, Franz Dienstl1, Erika Artner-Dworzak2, Bernd Puschendorf2, and Johannes Mair2,a

Departments of
1 Internal Medicine and
2 Medical Chemistry and Biochemistry, University of Innsbruck, A-6020 Innsbruck, Austria.
a Address correspondence to this author at: Institut für Medizinische Chemie & Biochemie, Fritz-Pregl Str. 3, A-6020 Innsbruck, Austria. Fax 43 512 507 2876; e-mail Johannes.Mair{at}uibk.ac.at.

Plasma concentrations of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor type 1 (PAI-1), and D-dimer were investigated in 50 patients treated intravenously for acute myocardial infarction with either streptokinase (n = 23), urokinase (n = 17), or recombinant t-PA (rt-PA, n = 10). The fibrinolytic variables were measured by enzyme immunoassay on admission; 1, 2, 4, 6, 8, 12, and 24 h later; and then daily until day 7 after admission. In each subgroup of patients treated with different thrombolytic agents, PAI-1 increased significantly (P <0.01) ~3 h after cessation of thrombolytic therapy. PAI-1 peak concentrations did not differ significantly (P = 0.82) among these three subgroups. t-PA and D-dimer did not differ significantly (P >0.14) among subgroups except for higher t-PA in the rt-PA group attributable to detection of the therapeutically administered exogenous rt-PA by the t-PA assay. Our findings demonstrate a marked PAI-1 increase after thrombolytic therapy for acute myocardial infarction, which seems to be a common, drug-independent antifibrinolytic rebound phenomenon in response to thrombolytic treatment.




The following articles in journals at HighWire Press have cited this article:


Home page
 StrokeHome page
D. Tanne, R. F. Macko, Y. Lin, B. C. Tilley, S. R. Levine, and for the NINDS rtPA Stroke Study Group
Hemostatic Activation and Outcome After Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke
Stroke, July 1, 2006; 37(7): 1798 - 1804.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. Chaudhuri, D. Janicke, M. F. Wilson, D. Tripathy, R. Garg, A. Bandyopadhyay, J. Calieri, D. Hoffmeyer, T. Syed, H. Ghanim, et al.
Anti-Inflammatory and Profibrinolytic Effect of Insulin in Acute ST-Segment-Elevation Myocardial Infarction
Circulation, February 24, 2004; 109(7): 849 - 854.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.